Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
grade D 34.14 0.95% 0.32
ALKS closed up 0.95 percent on Friday, January 18, 2019, on 1.12 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ALKS trend table...

Date Alert Name Type % Chg
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 50 DMA Support Bullish 0.95%
Jan 17 MACD Bullish Centerline Cross Bullish 0.95%
Jan 17 Pocket Pivot Bullish Swing Setup 0.95%
Jan 17 Upper Bollinger Band Walk Strength 0.95%

Older signals for ALKS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Is ALKS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 71.22
52 Week Low 27.54
Average Volume 957,716
200-Day Moving Average 41.2931
50-Day Moving Average 33.2566
20-Day Moving Average 30.7975
10-Day Moving Average 32.587
Average True Range 1.2582
ADX 21.94
+DI 24.5243
-DI 13.9981
Chandelier Exit (Long, 3 ATRs ) 30.5654
Chandelier Exit (Short, 3 ATRs ) 31.3146
Upper Bollinger Band 34.7819
Lower Bollinger Band 26.8131
Percent B (%b) 0.92
BandWidth 25.874828
MACD Line 0.1614
MACD Signal Line -0.4994
MACD Histogram 0.6608
Fundamentals Value
Market Cap 5.25 Billion
Num Shares 154 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -26.47
Price-to-Sales 10.50
Price-to-Book 7.03
PEG Ratio -1145.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.25
Resistance 3 (R3) 35.15 34.67 35.07
Resistance 2 (R2) 34.67 34.39 34.73 35.00
Resistance 1 (R1) 34.41 34.22 34.54 34.51 34.94
Pivot Point 33.93 33.93 34.00 33.99 33.93
Support 1 (S1) 33.67 33.65 33.80 33.77 33.34
Support 2 (S2) 33.19 33.48 33.25 33.28
Support 3 (S3) 32.93 33.19 33.22
Support 4 (S4) 33.03